首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VEGFC |
| Uniprot No | P49767 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 112-227aa |
| 氨基酸序列 | AHYNTEILKSIDNEWRKTQCMPREVCIDVGKEFGVATNTFFKPPCVSVYR CGGCCNSEGLQCMNTSTSYLSKTLFEITVPLSQGPKPVTISFANHTSCRC MSKLDVYRQVHSIIRR |
| 预测分子量 | 46 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"VEGF-C signaling pathways involved in lymphatic vessel formation"** (Karkkainen et al., 2004)
摘要：研究揭示了VEGFC通过激活VEGFR3受体促进淋巴管内皮细胞增殖和迁移，证实重组VEGFC蛋白在胚胎发育和病理条件下淋巴管生成中的关键作用。
2. **"Therapeutic induction of lymphatic growth via VEGFC reduces tissue inflammation"** (Huggenberger et al., 2011)
摘要：通过动物模型证明重组VEGFC蛋白可促进淋巴管新生，减轻慢性炎症和水肿，为治疗炎症性疾病提供潜在策略。
3. **"VEGF-C promotes tumor metastasis via lymphatic vessels"** (Skobe et al., 2001)
摘要：发现肿瘤细胞分泌的VEGFC通过增强淋巴管生成促进癌细胞转移，重组VEGFC蛋白的应用加速了小鼠模型中淋巴转移进程。
4. **"Recombinant VEGF-C administration improves cardiac repair post-myocardial infarction"** (Li et al., 2018)
摘要：实验显示重组VEGFC蛋白通过增强淋巴管再生和减少纤维化，改善心肌梗死后心脏功能，为心血管修复提供新方向。
Vascular endothelial growth factor C (VEGFC) is a secreted glycoprotein belonging to the VEGF family, primarily recognized for its critical role in lymphatic system development and vascular biology. It binds to tyrosine kinase receptors VEGFR-3 (Flt4) and VEGFR-2. activating downstream signaling pathways that regulate lymphangiogenesis (formation of lymphatic vessels) and angiogenesis (formation of blood vessels). VEGFC is essential during embryogenesis and maintains lymphatic homeostasis in adults. Dysregulation of VEGFC is implicated in pathological conditions, including tumor metastasis (via promoting lymphatic invasion), lymphedema, and inflammatory diseases.
Recombinant VEGFC protein is engineered using biotechnological methods, typically expressed in mammalian cell systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and bioactivity. The protein is purified via affinity chromatography and rigorously tested for endotoxin levels, sterility, and functional activity using cell-based assays. Researchers utilize recombinant VEGFC to study lymphatic/vascular biology, screen drug candidates targeting VEGFR-3 signaling, and explore therapeutic applications. For example, preclinical studies investigate its potential to treat lymphedema by stimulating lymphatic regeneration or to inhibit cancer progression by blocking VEGFC-receptor interactions.
Despite its promise, challenges remain in optimizing delivery methods, minimizing off-target effects, and understanding context-dependent roles in diseases. Ongoing research aims to refine recombinant VEGFC formulations for clinical translation while elucidating its complex interactions in tissue microenvironments.
×
